News & Updates
Filter by Specialty:

Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
Researchers from the University of Hong Kong (HKU) have developed a dry powder formulation of tamibaroterone, which displays broad-spectrum antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), and pandemic 2009 influenza A virus (H1N1), when delivered intranasally or through inhalation in mouse and hamster models.
Tamibaroterone inhalable dry powder shows broad-spectrum activity against SARS-CoV-2, MERS and H1N1
12 Oct 2021
Aspirin slows down metabolic clock of gestation, reduces risk of pre-eclampsia
Recent research by the Chinese University of Hong Kong (CUHK) and Baylor College of Medicine discovers that aspirin’s benefit in preventing pre-eclampsia is mediated through decelerating the metabolic clock of gestation.
Aspirin slows down metabolic clock of gestation, reduces risk of pre-eclampsia
12 Oct 2021
Early convalescent plasma infusion does not prevent COVID-19 progression
An infusion of convalescent plasma, obtained via blood donation from individuals who have recovered from COVID-19, did not prevent disease progression in high-risk outpatients who presented within 7 days of COVID-19 symptom onset, results of the phase III US-based SIREN-C3PO* study showed.
Early convalescent plasma infusion does not prevent COVID-19 progression
11 Oct 2021
Diet plus exercise keeps BP in check for patients with resistant hypertension
A structured lifestyle modification programme that combines a healthy eating plan and regular aerobic exercise promotes blood pressure (BP) control and improves cardiovascular disease biomarkers in patients with resistant hypertension, as shown in the TRIUMPH study.
Diet plus exercise keeps BP in check for patients with resistant hypertension
11 Oct 2021
POETYK trials highlight potential of novel drug for plaque psoriasis
The investigational, first-in-class, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib showed durable efficacy for the treatment of moderate-to-severe plaque psoriasis*, according to the 52-week efficacy analysis results of the POETYK** PSO-1 and POETYK PSO-2 trials presented at EADV 2021.




